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Abstract
Background: The role of adenosine and ATP in the regulation of hepatic arterial blood flow in
the "buffer response" was studied in vitro and in a new in vivo model in the rabbit. The model
achieves portal-systemic diversion by insertion of a silicone rubber prosthesis between the portal
vein and inferior vena cava and avoids alterations in systemic haemodynamics.
Results: Hepatic arterial (HA) blood flow increased in response to reduced portal venous (PV)
blood flow, the "buffer response", from 19.4 (3.3) ml min-1 100 g-1 to 25.6 (4.3) ml min-1 100 g-1
(mean (SE), p < 0.05, Student's paired t-test). This represented a buffering capacity of 18.7 (5.2) %.
Intra-portal injections of ATP or adenosine (1 micrograms kg-1-0.5 mg kg-1) elicited immediate
increases in HA blood flow to give -log ED50 values of 2.0 and 1.7 mg kg-1 for ATP and adenosine
respectively. Injection of ATP and adenosine had no measurable effect on PV flow. In vitro, using an
isolated dual-perfused rabbit liver preparation, the addition of 8-phenyltheophylline (10
MicroMolar) to the HA and PV perfusate significantly inhibited the HA response to intra-arterial
adenosine and to mid-range doses of intra-portal or intra-arterial ATP (p < 0.001).
Conclusions: It is suggested that HA vasodilatation elicited by ATP may be partially mediated
through activation of P1-purinoceptors following catabolism of ATP to adenosine.
Background
The hepatic arterial (HA) hyperaemic response to portal
vein (PV) occlusion, the hepatic arterial "buffer response"
[1], is thought to be mediated by adenosine. Studies con-
ducted in the cat demonstrated both inhibition of the
buffer response by the adenosine receptor antagonist, 8-
phenyltheophylline, and potentiation by the adenosine
uptake inhibitor dipyridamole [2]. Further studies how-
ever, suggested that adenosine was not the sole agent
responsible in the dog and other species [3-6].
Adenosine-5'-triphosphate (ATP) has been proposed to
play an important role in the control of systemic [7,8] and
hepatic vascular tone [9] and may therefore be a candidate
for a role in the buffer response. ATP has been shown to
be released from blood constituents [10] and vascular
endothelium [11,12] during hypoxia [13] or altered flow
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conditions [14] which may be encountered during reduc-
tion or total occlusion of portal venous blood flow.
Defined criteria have been proposed which must be ful-
filled for a substance to be considered as a regulator of the
buffer response [2]. These included: 1) the substance must
dilate the hepatic artery; 2) substances in portal blood
must have access to hepatic arterial resistance sites; 3)
potentiators of the substance should also potentiate the
buffer response; and 4) inhibitors of the substance should
inhibit the buffer response. ATP has been shown to dilate
the isolated hepatic artery [15] and the hepatic arterial
vascular bed of the rabbit in vitro [9] and has been shown
to act via the release of nitric oxide (NO) [16]. A similar
mechanism is at least partly responsible for the hepatic
arterial vasodilatation seen following portal venous injec-
tion of ATP in the same model [17]. In most vessels, ATP
has been shown to elicit vasodilatation by stimulation of
purinergic P2y receptors, generally located in the vascular
endothelium [9] although they may also be on HA vascu-
lar smooth muscle in the rabbit [15]. In some vessels how-
ever, ATP, which is rapidly catabolised to adenosine-5'-
diphosphate (ADP), adenosine-5'-monophosphate
(AMP) and adenosine in endothelial cells and vascular
smooth muscle cells [18], causes vasodilatation via P1-
purinoceptors [19]. Total catabolism of ATP to ADP, AMP
or adenosine would therefore raise the possibility that all
previous findings relating to the buffer response were con-
sistent with release of ATP alone. However, this mecha-
nism of action of ATP is not believed to occur in the rabbit
liver [9].
In vivo studies are required to confirm whether ATP is
involved in the generation of the buffer response because
it cannot be demonstrated in the in vitro perfused rabbit
liver (Browse and Alexander, unpublished observation).
In addition, current Home Office restrictions and eco-
nomical factors which influence the use of larger animal
models for experimentation has restricted in vivo studies
in the UK although a feasibility study conducted in the
Asian hybrid minipig in our laboratories proved unsuc-
cessful [4]. The purpose of the present study therefore, was
to develop an in vivo model for the assessment of liver
blood flow in the rabbit to compare with our in vitro dual-
perfused rabbit liver model [20] in order to establish
whether ATP is involved in the generation of the buffer
response.
Results
In vivo
In a number of experiments irreversible hypotension (n =
2), respiratory depression (n = 2) and acidosis (n = 2)
occurred during the temporary occlusion of the portal
vein for the insertion of the mesocaval shunt and data
from these preparations have therefore not been included.
It was imperative that haemodynamic stability should be
attained before measurements were conducted and this
was achieved in 5 preparations presented here. HA flow
(HAF) was 19.4 (3.3) ml min-1 100 g-1, PV flow (PVF) 85.5
(19.3) ml min-1 100 g-1 and mean arterial pressure was
80.2 (5.8) mmHg. When the mesocaval shunt was opened
and the mesenteric vein occluded PVF decreased to 38.5
(3.7) ml min-1 100 g-1 and HAF increased to 25.6 (4.3) ml
min-1100 g-1 (p < 0.05, Figure 2a) a calculated buffering
capacity of 18.7 (5.2) % (Table 1, n = 5). During portal
venous flow reduction the mean arterial pressure consist-
ently rose to 85.2 (5.2) mmHg, (p < 0.001). When the
portal venous flow was re-established there was often a
small rebound portal "hyperaemia" accompanied by a
temporary fall in HA flow and a fall in systemic blood
pressure (Figure 2b).
In the 5 experiments described above HAF and PVF were
stable for a sufficiently long period to allow the construc-
tion of dose-response curves for HA flow responses to
intra-portal injection of adenosine or ATP. Intraportal
injection of ATP and adenosine both caused immediate
increases in HAF (Figure 3) and the -log ED50 values (cal-
culated from the graph) for these agents were 2.0 mg kg-1
and 1.7 mg kg-1 for ATP and adenosine respectively. Injec-
tion of ATP and adenosine had no measurable effect on
PV flow.
In vitro
Group 1. The effect of intra-arterial ATP
Livers from 6 rabbits [body weight 2.93 (0.14) kg, liver
weight 119.2 (13.4) g] were perfused at raised tone [HAP
146.7 (7.7) and PVP 3.3 (0.8) mmHg]. The effect of the
addition of 8-SPT to the hepatic arterial and portal venous
perfusate was evaluated using previously calculated mid-
range doses of adenosine, ACh and sodium nitroprusside
[16]. 8-SPT (10 µM) significantly inhibited the HA
response to 10-7moles 100 g liver-1 intra-arterial adenos-
ine from 50.8 (6.2) to 31.6 (8.1) mmHg (p < 0.05), but
did not significantly inhibit HA responses to 10-8moles
100 g liver-1intra-arterial ACh [68.9 (6.6) to 72.2 (5.7)
mmHg] or to 10-8moles 100 g liver-1intra-arterial SNP
[36.3 (4.4) to 41.6 (9.7) mmHg]. The dose-related
response curve to intra-arterial ATP was also shifted to the
right by 8-SPT [-log Molar ED50 8.70 (0.22) to 7.63 (0.28),
p < 0.001] indicating inhibition of responses to ATP (Fig-
ure 4a). The amplitude of portal venous responses to
intra-arterial ATP correlated with the duration of per-
fusion (Figure 4b).
Group 2. The effect of intra-portal ATP
Livers from another group of 6 rabbits [body weight 2.60
(0.14) kg, liver weight 98.8 (5.2) g] were perfused at raised
tone [HAP 156.2 (4.8) and PVP 2.3 (0.7) mmHg]. The
addition of 8-SPT to the hepatic arterial and portal venousComparative Hepatology 2003, 2 http://www.comparative-hepatology.com/content/2/1/9
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perfusate significantly inhibited the HA response to 10-8
moles 100 g liver-1  intra-arterial adenosine from 33.2
(3.5) to 6.5 (3.8) mmHg (p < 0.001). The HA dose-related
responses to mid-range doses of intra-portal ATP were
also significantly reduced by 8-SPT, causing a non-signifi-
cant right shift of the dose-response curve to ATP from -
log Molar ED50 5.08 (0.15) to 4.97 (0.12) (p = 0.05) (Fig-
ure 5a). The portal venous responses to intra-portal injec-
tions of ATP were not significantly altered by 8-SPT
(Figure 5b).
Discussion
A new model for the study of liver blood flow in the rabbit
has been presented, based on a concept developed in the
dog [6,21]. The preparation employed a mesocaval shunt
to divert blood to the systemic circulation during portal
venous occlusion to prevent the fall in systemic blood
pressure due to mesenteric pooling of portal blood [22].
This model is also closer to physiological portal venous
flow conditions than models where splenectomy is neces-
sary [2,23]. The insertion of the prosthetic mesocaval
Diagram of silastic H-shaped prosthesis inserted into the portal vein and the inferior vena cava of the in vivo rabbit model Figure 1
Diagram of silastic H-shaped prosthesis inserted into the portal vein and the inferior vena cava of the in vivo rabbit model. Dur-
ing control conditions, the prosthesis is clamped across the horizontal limb at "a". Portal-systemic diversion is achieved by 
removal of the clamp from "a" and cross-clamping at point "b", distal to the point of entry of the splenic vein into the portal 
vein.Comparative Hepatology 2003, 2 http://www.comparative-hepatology.com/content/2/1/9
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shunt, which required a brief period of PV occlusion, can
cause irreversible systemic hypotension, and this reduced
the success rate. Experiments are in progress to improve
this model further by the surgical construction of a meso-
caval shunt, although this is difficult due to the fragility of
the rabbit portal vein. Nevertheless a hepatic arterial
buffer response could be clearly demonstrated in all the
successful preparations. During portal venous occlusion
the mean arterial blood pressure also increased but this
was insufficient to account for the increase in hepatic arte-
rial flow. This model, if further developed, may therefore
prove to be an alternative to experimental models in the
cat and dog for investigations of this nature.
The action of ATP in this in vivo rabbit liver model was
also demonstrated. Intra-portal injection of ATP or adeno-
sine elicited a potent vasodilatation of the hepatic artery.
This action occurred over a similar dose range to that
observed in our in vitro perfused rabbit liver model [17].
The HA dilator action of intra-portal ATP fulfilled the first
two criteria defined by Lautt [2], equivalent to the first cri-
terion originally proposed by Dale [24], in order to be
considered as a regulator of the buffer response, namely
that the addition of ATP elicited the appropriate response
(vasodilatation of the HA) and portal injection of ATP
permitted access to the arterial resistance sites. In addi-
tion, antagonists of adenosine, the catabolite of ATP,
although indirect, partially attenuated the response, thus
fulfilling the second of Dale's postulates. However, further
experiments using inhibitors of these agents have proved
difficult in the past and often resulted in haemodynamic
instability [6] or prolonged hepatic arterial vasospasm
[25]. Thus we used our comparable in vitro model as an
alternative preparation for these investigations.
We have previously shown that intra-portal or intra-arte-
rial injection of ATP dilated the rabbit HA vascular bed,
and that this was mediated, at least in part, by NO [16,17].
However, in other vessels ATP has been shown to act via
adenosine receptors [19]. We therefore tested whether
some of the HA dilatation to ATP was attributable to
catabolism to adenosine by using the non-selective P1-
purinoceptor antagonist 8-SPT [26].
Our results demonstrated that both intra-arterial and
intra-portal injection of ATP caused HA vasodilatation, at
least in part, through activation of P1-purinoceptors. The
way in which 8-SPT inhibited responses to ATP was of
interest. The responses to lower doses of ATP were unaf-
fected, as expected, because ATP is a more potent vasodi-
lator than adenosine, but the 'middle range' doses of ATP
were certainly inhibited, while higher doses were not.
These data do not contradict our earlier findings where
HA vasodilatation to ATP did not appear to be affected by
8-SPT [9]. The previous study only reported the action of
8-SPT at the two highest doses of ATP used, due to
constraints of time upon the viability of the preparation,
since characterised in greater detail by Browse et al [27].
The data points at the two highest doses used in this study
conformed with these since only responses to mid-range
doses of ATP were significantly attenuated. This may have
been due to the overwhelming of competitive inhibition
at high doses or have been indicative of a different mech-
anism of ATP and/or adenosine action [28].
There was no apparent difference in the degree of inhibi-
tion of HA responses by 8-SPT between intra-arterial and
intra-portal injection of ATP despite a longer lag-time
between injection and response following intra-portal
injection of ATP. This might suggest that nearly all the
adenosine produced from ATP catabolism was taken up
effectively by the endothelium and vascular smooth mus-
cle [18] as soon as the adenosine was formed, and that
only the adenosine formed in the hepatic arterial vascula-
ture from ATP catabolism contributed to the hepatic arte-
rial response to ATP. This occurred despite the presumably
higher concentration of adenosine in the liver as a whole
following intra-portal (10-8 - 10-4 log moles ATP 100 g
liver-1) compared with intra-arterial injections (10-10 - 10-
6 log moles ATP 100 g liver-1) of ATP.
This 8-SPT-induced inhibition of responses to ATP raises
the possibility that, in studies where 8-SPT reduced the
The hepatic arterial buffer response during portal venous  occlusion Figure 2
The hepatic arterial buffer response during portal venous 
occlusion. There was a significant increase in hepatic arterial 
flow during portal venous occlusion (* p < 0.05) compared to 
basal hepatic arterial flow. HAF = hepatic arterial flow, PVF = 
portal venous flow and MAP = mean arterial pressure.Comparative Hepatology 2003, 2 http://www.comparative-hepatology.com/content/2/1/9
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The effect of intra-portal injection of (a) ATP and (b) adenosine on changes in hepatic arterial flow (∆ HAF) in vivo Figure 3
The effect of intra-portal injection of (a) ATP and (b) adenosine on changes in hepatic arterial flow (∆ HAF) in vivo. Both agents 
increased hepatic arterial flow in a dose-dependent manner. The error bars in the graphs represent the SE.Comparative Hepatology 2003, 2 http://www.comparative-hepatology.com/content/2/1/9
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magnitude of the buffer response [2,6], the primary agent
responsible for the buffer response could have been ATP
and not adenosine. Further studies will be required to dis-
tinguish between these two agents. Firstly, the inhibition
by 8-SPT of the ATP induced HA vasodilatation must be
shown to occur in vivo. Secondly, if ATP is the primary
agent, the buffer response may also be, at least partially,
inhibited by an NO synthesis inhibitor because we have
previously reported that ATP-induced but not adenosine-
induced HA vasodilatation is attenuated by such an inhib-
itor in the rabbit liver [6]; and thirdly, vascular responses
to adenosine must be shown to be independent of NO,
because recent evidence from the hypoxic guinea-pig
heart has suggested that adenosine may act via A2-purino-
ceptors to release nitric oxide [29] and this point should
be considered in this model.
Conclusions
In summary, a new in vivo rabbit liver model for the inves-
tigation of liver blood flow has been presented which,
although at an early stage of development, may prove to
be a useful model. The hepatic arterial buffer response and
the hepatic arterial vasodilatation elicited by ATP and by
adenosine have been consistently and reproducibly dem-
onstrated. In an established in vitro model, hepatic arterial
vasodilatation elicited by ATP has been shown to be partly
mediated through P1-purinoceptors suggesting that ATP
could have a role in the generation of the buffer response
in the rabbit liver.
Methods
Experiments were carried out in a total of 27 male New
Zealand white rabbits weighing 2.2 – 3.4 kg, fed and per-
mitted access to water ad libitum. The experimental proto-
cols were approved by the guidelines and legislative
procedures outlined by the Home Office of the United
Kingdom in the Animal Scientific Procedures Act 1986.
Pre-operative sedation was with fentanyl/fluanisone s.c.
('Hypnorm', 0.3 ml kg-1, Janssen Animal Health).
In vivo experiments (n = 15)
Anaesthesia was induced in rabbits [2.8 (0.1) kg] with
midazolam ('Hypnovel', 0.3 ml kg-1, Roche Products Lim-
ited) and maintained with a continuous infusion of 'Hyp-
norm' (0.1 – 0.3 ml kg-1  hr-1) through a cannulated
marginal ear vein. The rabbits were intubated but allowed
to breathe spontaneously. The inspired oxygen was
adjusted to maintain arterial PO2 and PCO2 at normal lev-
els (approximately 100 mmHg and 40 mmHg,
respectively) and body temperature was kept at 36–38°C
by operating table heating elements. Fluid balance was
achieved by intravenous infusion of 150 mM sodium
chloride and acid-base balance maintained by injection of
sodium bicarbonate as required.
Operative procedure
The experimental preparation was based upon a model we
have previously established in the dog [21,30]. After can-
nulation of the carotid artery for blood pressure monitor-
ing, a midline laparotomy was performed and the inflow
vessels to the liver dissected. The gastroduodenal artery
and vein were ligated and divided. A prosthetic (H-
shaped) mesocaval shunt, constructed from 3.0 mm inter-
nal diameter silicone rubber tubing, was inserted proxi-
mal to the splenic vein after heparinisation (300 iu. kg-1
i.v.). This allowed diversion of mesenteric blood flow to
the systemic circulation as required. A clamp was placed
on the cross limb of the "H" to restore portal flow. Pre-cal-
ibrated electromagnetic flow probes (Statham) were
applied to the common hepatic artery and portal vein (1
and 3 mm diameter respectively) (Figure 1).
Experimental protocol
After 1 hour equilibration, the effect of a reduction in PV
flow on HA flow (i.e. the buffer response) was tested. PV
flow was reduced by clamping the mesenteric vein,
proximal to the insertion of the splenic vein, and opening
the mesocaval shunt for 3 min. This procedure, which
diverts mesenteric flow into the systemic circulation
reduces portal flow to that of splenic vein flow was con-
Table 1: The effect of portal venous flow (PVF) reduction on hepatic arterial flow (HAF) and mean arterial blood pressure (MAP).
BEFORE PORTAL VENOUS OCCLUSION AFTER PORTAL VENOUS OCCLUSION
Exp. no. n HAF (ml. min-
1.100 g-1)
PVF (ml. min-
1.100 g-1)
MAP (mmHg) HAF (ml. min-
1.100 g-1)
PVF (ml. min-
1.100 g-1)
MAP (mmHg) HAF increase 
(%)
Buffering 
capacity (%)
1 4 16.9 143.2 95.0 25.3 39.1 96.8 66.8 8.9
2 2 17.5 64.2 67.5 22.5 35.0 72.5 28.5 17.6
3 2 9.4 63.5 70.0 11.4 48.5 75.0 22.0 15.1
4 6 25.4 70.9 75.0 36.7 31.5 84.2 40.3 33.2
5 3 27.8 - 93.3 32.1 - 97.3 15.3 -
Mean (SE) - 19.4 (3.3) 85.5 (19.3)* 80.2 (5.8)* 25.6 (4.3) 38.5 (3.7) 85.2 (5.2) 34.6 (9.1) 18.7 (5.2)
Each value is the mean of the number of observations stated. Both HAF and MAP increased significantly during PV occlusion (* p < 0.05, n = 5).Comparative Hepatology 2003, 2 http://www.comparative-hepatology.com/content/2/1/9
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The changes in (a) hepatic arterial pressure responses (∆ HAP) and (b) portal venous pressure responses (∆ PVP) to intra-arte- rial injection of ATP Figure 4
The changes in (a) hepatic arterial pressure responses (∆ HAP) and (b) portal venous pressure responses (∆ PVP) to intra-arte-
rial injection of ATP. The adenosine receptor antagonist 8-phenyltheophylline (10 µM) significantly decreased hepatic arterial 
responses to ATP, while portal venous responses were unaffected (* p < 0.05, ** p < 0.01, compared with before 8-SPT). The 
error bars in the graphs represent the SE.Comparative Hepatology 2003, 2 http://www.comparative-hepatology.com/content/2/1/9
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The changes in (a) hepatic arterial pressure responses (∆ HAP) and (b) portal venous pressure responses (∆ PVP) to intra-por- tal injection of ATP Figure 5
The changes in (a) hepatic arterial pressure responses (∆ HAP) and (b) portal venous pressure responses (∆ PVP) to intra-por-
tal injection of ATP. The adenosine receptor antagonist 8-phenyltheophylline (10 µM) significantly decreased hepatic arterial 
responses to ATP, while portal venous responses were unaffected (** p < 0.01, compared with before 8-SPT). The error bars 
in the graphs represent the SE.Comparative Hepatology 2003, 2 http://www.comparative-hepatology.com/content/2/1/9
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ducted at least twice per experiment (see Table 1). Meas-
urement of the buffer response was then recorded as
absolute flow values from the precalibrated electromag-
netic flow probes. Hepatic blood flow was then restored
by removal of the vascular clamp on the PV, and reappli-
cation of the anastomotic clamp to the cross-limb of the
H-shunt.
When haemodynamic stability had been achieved, incre-
mental doses of ATP or adenosine (1 µg kg-1 – 0.5 mg kg-
1) (Sigma U.K. Ltd), dissolved in saline, were injected into
the portal vein and changes in HA or PV blood flow could
again be recorded as absolute values from the precali-
brated electromagnetic flow meters. Dose-response curves
of changes in blood flow vs dose of drug injected were
then constructed.
Calculations
Blood flows were recorded on the flowmeters in ml min-1
and subsequently recalculated in ml min-1 100 g-1 by relat-
ing the readings to the wet weight of the liver, determined
at the end of each experiment. The "buffering capacity" of
the HA was expressed in % as:
[Increase in HA flow / Decrease in PV flow] × 100
In vitro experiments (n = 12)
Twelve rabbits were anaesthetised with Hypnovel (mida-
zolam) 1.5 mg kg-1 i.v., and a further 0.3 ml kg-1 Hypnorm
was injected i.m. for continued analgesia during the 40
minute operative period. The operative technique has
been described in detail elsewhere [20] but will be out-
lined in brief here. The abdomen was opened though a
mid-line incision, and the common bile duct cannulated
to facilitate exposure and cannulation of the common
hepatic and gastroduodenal artery in addition for the col-
lection of bile during perfusion. After administration of
heparin i.v. (300 units kg-1) the common hepatic artery
and the gastroduodenal artery were cannulated (Portex
3FG). Ten ml of heparinised saline (20 units ml-1) were
infused into the catheters to prevent intrahepatic coagula-
tion. The gastroduodenal vein was ligated, the PV cannu-
lated and 40 ml of heparinised saline flushed through the
PV system. The liver was then rapidly excised from the ani-
mal, weighed and placed in an organ bath.
Liver perfusion
Livers were perfused via the HA and PV cannulae at con-
stant flow rates of 25 and 75 ml min-1 100 g liver-1 respec-
tively. The perfusate used was Krebs-Bülbring buffer
solution (composition mmoles L-1: NaCl 133, KCl 4.7,
NaH2PO4 1.35, NaHCO3 20.0, MgSO4 0.61, Glucose 7.8,
and CaCl2 2.52) at 37°C, from a common oxygenated res-
ervoir (95% O2: 5% CO2). Homogeneous liver perfusion
was indicated by all sections of the liver changing to a uni-
form colour. Changes in vascular tone were recorded as
changes in perfusion pressure measured with Spectramed
(Statham) P23XL physiological pressure transducers from
side arms of the perfusion circuit and from the gastroduo-
denal artery cannula. These were recorded on a Grass 79 F
polygraph (Grass Instrument Co., Quincy, Mass., USA).
Perfusion under these conditions maintains liver viability
for 5 hours [27].
Experimental protocol
Methoxamine was added to the perfusate at a -log Molar
concentration of 5.27 (0.05) to raise the tone of the prep-
aration. Two groups of rabbits were studied: ATP injection
into the HA (Group 1), and ATP injection into the PV
(Group 2). Dose response curves were constructed to ATP
(10-10 to 10-6 moles 100 g liver-1 for intra-arterial, and 10-
8 to 10-4 moles 100 g liver-1 for intra-portal injection) and
repeated after a 15 minute equilibration period following
the addition of the water soluble derivative of 8-phe-
nyltheophylline (8-PT, 8-(p-sulphophenyl)-theophylline
(8-SPT) (Research Biochemicals Inc.), to the arterial and
venous perfusate. Single HA doses of acetylcholine (ACh,
10-7 moles 100 g liver-1) and/or sodium nitroprusside
(SNP, 10-8  moles 100 g liver-1) were given at regular
intervals throughout the experiment to confirm the main-
tenance of the vascular responses with time, while intra-
arterial doses of 10-7 moles 100 g liver-1 adenosine (the
catabolite of ATP) were given to confirm inhibition by 8-
SPT [6,16]. All drugs were made up in saline.
Statistical analysis
The data was confirmed to be normally distributed using
Kolmogorov-Smirnov test and also that the variances of
the data were not significantly different using Graphpad,
copyright 1994–1996 by GraphPad Software Inc. Stu-
dent's paired t-test was therefore used to test the signifi-
cance of differences between observations before and after
PV occlusion, and the magnitude of vascular responses to
ATP before and during administration of 8-SPT. Signifi-
cance level was always taken at α = 0.05. All data are pre-
sented as mean (SE).
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